Market Place
Sourcing Support
Puma Bio Discloses Inducement Awards Per Nasdaq LR 5635(C)(4)
02 Dec 2025 //
BUSINESSWIRE
Puma Bio Discloses Inducement Awards Per Nasdaq LR 5635(C)(4)
07 Nov 2025 //
BUSINESSWIRE
Puma Bio Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
07 Jun 2024 //
BUSINESSWIRE
Puma`s Alisertib Phase 1/1b Data In Advanced EGFR-Mutant Lung Cancer
03 Jun 2024 //
BUSINESSWIRE
Puma`s Alisertib Shows Findings In Endocrine-Resistant Metastatic Breast Cancer
02 Jun 2024 //
BUSINESSWIRE
Puma Alisertib Asco Abstracts: 2024 Annual Meeting Titles Published
23 May 2024 //
BUSINESSWIRE
Pfizer wins $107.5M from AZ in US cancer drug patent trial
18 May 2024 //
REUTERS
Puma Biotechnology Reports First Quarter Financial Results
02 May 2024 //
BUSINESSWIRE
Puma Announces FDA Allowance to Proceed Under IND for Alisertib in Breast Cancer
20 Mar 2024 //
BUSINESSWIRE
Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results
29 Feb 2024 //
PRESS RELEASE
Puma Bio Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
27 Feb 2024 //
BUSINESSWIRE
Puma Bio to Participate in Panel Discussion at TD Cowen’s 44th Annual Conference
22 Feb 2024 //
BUSINESSWIRE
Puma to Host Conference to Discuss Q4 and Full Year 2023 Financial Results
15 Feb 2024 //
PRESS RELEASE
Puma Bio Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib
13 Feb 2024 //
BUSINESSWIRE
Puma Bio to Present at B. Riley Securities 4th Annual Oncology Conference
11 Jan 2024 //
BUSINESSWIRE
Puma Biotechnology Reports Third Quarter 2023 Financial Results
02 Nov 2023 //
BUSINESSWIRE
Puma Bio to Host Conference Call to Discuss Third Quarter 2023 Financial Results
19 Oct 2023 //
BUSINESSWIRE
Puma Bio Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04 Oct 2023 //
BUSINESSWIRE
Puma Biotechnology to Present at the H.C. Wainwright 25th Conference
31 Aug 2023 //
BUSINESSWIRE
Puma Bio Announces FDA Clearance of IND for Alisertib in Small Cell Lung Cancer
08 Aug 2023 //
BUSINESSWIRE
Puma Biotechnology Reports Second Quarter Financial Results
03 Aug 2023 //
BUSINESSWIRE
Puma Bio to Host Conference to Discuss Second Quarter 2023 Financial Results
20 Jul 2023 //
BUSINESSWIRE
Puma Bio Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
06 Jun 2023 //
BUSINESSWIRE
Puma Biotechnology Reports First Quarter Financial Results
04 May 2023 //
BUSINESSWIRE
Puma Biotechnology to Host Conference Call to Discuss 1Q 2023 Financial Results
20 Apr 2023 //
BUSINESSWIRE
Puma Bio Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
11 Apr 2023 //
BUSINESSWIRE
Puma Bio Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
03 Mar 2023 //
BUSINESSWIRE
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
02 Mar 2023 //
BUSINESSWIRE
Puma to Participate in a Panel Discussion at Annual Health Care Conference
28 Feb 2023 //
BUSINESSWIRE
Puma Biotechnology to Discuss Fourth Quarter 2022 Financial Results
16 Feb 2023 //
BUSINESSWIRE
Puma Bio Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
07 Feb 2023 //
BUSINESSWIRE
Puma Biotechnology Presents Updated Findings from the TBCRC-022 Trial
07 Dec 2022 //
BUSINESSWIRE
Puma Biotechnology Reports Third Quarter 2022 Financial Results
03 Nov 2022 //
BUSINESSWIRE
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635
02 Nov 2022 //
BUSINESSWIRE
Puma Biotechnology Presents Updated Findings from the PII Trial of Neratinib
27 Oct 2022 //
BUSINESSWIRE
Puma Bio to Host Conference Call to Discuss Third Quarter Financial Results
20 Oct 2022 //
BUSINESSWIRE
Puma Biotech Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04 Oct 2022 //
BUSINESSWIRE
Puma Announces Agreement with Takeda for the Development of Alisertib
21 Sep 2022 //
BUSINESSWIRE
Puma Presents Findings from the PII SUMMIT Basket Trial of Neratinib
11 Sep 2022 //
BUSINESSWIRE
Puma to Present at the H.C. Wainwright 24th Annual Global Investment Conference
06 Sep 2022 //
BUSINESSWIRE
Puma Bio Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
02 Sep 2022 //
BUSINESSWIRE
Puma Biotech Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
05 Aug 2022 //
BUSINESSWIRE
Puma Biotechnology Reports Second Quarter 2022 Financial Results
04 Aug 2022 //
BUSINESSWIRE
Puma Biotech Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
06 Jul 2022 //
BUSINESSWIRE
Puma Biotech Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
07 Jun 2022 //
BUSINESSWIRE
Puma Biotech Presents Outcomes from Metastatic Breast Cancer Cohort
06 Jun 2022 //
BUSINESSWIRE
Puma Bio Presents Results from Biliary Tract Cohort of PII Trial of Neratinib
04 Jun 2022 //
BUSINESSWIRE
Puma Biotechnology Announces Publication of Abstracts on Neratinib
26 May 2022 //
BUSINESSWIRE
Puma Biotech Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
11 May 2022 //
BUSINESSWIRE
Puma Biotechnology Reports First Quarter 2022 Financial Results
05 May 2022 //
BUSINESSWIRE
Puma Biotech Announces Publication of Neratinib Abstract Titles for 2022 ASCO
27 Apr 2022 //
BUSINESSWIRE
Puma Biotechnology to Host Conference Call to Discuss 1QFinancial Results
21 Apr 2022 //
BUSINESSWIRE
Puma Bio Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
05 Apr 2022 //
BUSINESSWIRE
Puma Biotechnology Announces $10 Million Private Placement
10 Mar 2022 //
BUSINESSWIRE
Puma Bio to Participate in Breast Cancer Panel at Cowen’s Annual Conference
07 Mar 2022 //
BUSINESSWIRE
Puma Biotech Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
04 Mar 2022 //
BUSINESSWIRE
Puma Biotechnology Reports Fourth Quarter and Full Year Financial Results
03 Mar 2022 //
BUSINESSWIRE
Puma Bio to Host Conference Call for Q4 and Full Year 2021 Financial Results
16 Feb 2022 //
BUSINESSWIRE
Puma Biotech Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
03 Feb 2022 //
BUSINESSWIRE
Puma Biotech Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
20 Jan 2022 //
BUSINESSWIRE
